According to iBio's latest financial reports the company's current revenue (TTM) is $0.05 M. In 2022 the company made a revenue of $1.86 M an increase over the years 2021 revenue that were of $1.34 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.05 M | -97.31% |
2022 | $1.86 M | 38.88% |
2021 | $1.34 M | -42.51% |
2020 | $2.33 M | 33.66% |
2019 | $1.74 M | 101.62% |
2018 | $0.86 M | 88.45% |
2017 | $0.45 M | -46.88% |
2016 | $0.86 M | -9.91% |
2015 | $0.95 M | -31.06% |
2014 | $1.39 M | 125.51% |
2013 | $0.61 M | -44.59% |
2012 | $1.11 M | 3.62% |
2011 | $1.07 M | |
2010 | N/A | -100% |
2009 | $0.46 M | -61.96% |
2008 | $1.21 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 186,043,900.00% | ๐บ๐ธ USA |
Genocea Biosciences
GNCA | $1.91 M | 3,722.00% | ๐บ๐ธ USA |
Nektar Therapeutics
NKTR | $90.12 M | 180,144.00% | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $1.02 B | 2,047,500.00% | ๐บ๐ธ USA |